Vera Therapeutics, Inc.
VERA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$27.99
KIRA · Stoqly’s AI analyst, in plain words
- Vera Therapeutics, Inc. lost $300M in fiscal 2025.
- Free cash flow was −$242M in fiscal 2025, — of revenue.
- Vera Therapeutics, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 16.1%.
- Vera Therapeutics, Inc. has $640M more cash than debt.
Market cap
$2.0B
P/E
—
Revenue
—
Net income
−$300M
Free cash flow
−$242M
Operating margin
—
Vera Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$300M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Vera Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Vera Therapeutics, Inc.
- CIK
- 0001831828
Vera Therapeutics, Inc. · VERA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$32.6M | −$89.1M | −$96.0M | −$152M | −$300M |
| Diluted EPS | −$2.43 | −$3.35 | −$2.25 | −$2.75 | −$4.66 |
| Cash | |||||
| Cash from operations | −$23.7M | −$67.6M | −$92.2M | −$135M | −$241M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $1.0M | $0.6M |
| Free cash flow | −$23.7M | −$67.7M | −$92.2M | −$136M | −$242M |
| Share buybacks | — | — | $0.0M | $0.0M | $0.0M |
| Share count change | 4,098.7% | 97.8% | 60.7% | 29.5% | 16.1% |
| Debt and strength | |||||
| Cash and short-term investments | $79.7M | $115M | $161M | $641M | $715M |
| Debt incl. finance leases | $4.9M | $24.8M | $49.9M | $50.7M | $74.8M |
| Shareholders' equity | $69.6M | $76.9M | $102M | $577M | $605M |
| Current ratio | 10.7x | 4.9x | 7.7x | 25.7x | 13.6x |
| Interest coverage | −1,720.1x | −91.6x | −26.9x | −21.9x | −41.9x |
| Returns and quality | |||||
| Return on equity | — | −121.6% | −107.5% | −44.8% | −50.7% |
| Return on tangible equity | −46.9% | −115.8% | −94.4% | −26.4% | −49.6% |
| Piotroski F-score | 2 | 1 | 3 | 4 | 1 |
| Altman Z'' | 3.4 | −3.5 | −2.6 | 10.0 | 4.6 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$9.0M
8 insiders
Of sales under plans
78%
$7.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Vera Therapeutics, Inc. · VERA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $27.99 a share, the company is worth $2.0B.
Source: SEC EDGAR XBRL filings (CIK 0001831828). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.